Biotech IV Monitor

MBX — MBX Biosciences Inc.

$3.0B market cap · 2 upcoming readouts tracked

Clinical trial readout dates for MBX Biosciences Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2028.

Next readoutJanuary 2028in ~14 months
Upcoming readouts21 Phase 3
Market cap$3.0B
Cash & investments$483M~8 quarters at last loss rate
Recent 8-K filings1latest 2026-11-09

Upcoming readouts

Phase 3 Canvuparatide
Hypoparathyroidism · NCT07699471
January 2028
Recruiting
Phase 2 400 µg of MBX 2109 once-weekly by subcutaneous injection
Hypoparathyroidism · NCT06531941
May 2028
Ongoing

Cash position

MBX Biosciences Inc. reported $483M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $62M; at that rate the cash would last about 8 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Reg FD Disclosure — often a data announcement2026-11-09

Discussion

No messages yet. If you follow MBX, you can start the conversation.
Track MBX in real time
See live implied volatility for MBX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on MBX
Contact — questions or corrections about MBX: dukeupt@gmail.com